Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Larimar Therapeutics Q2 2024 GAAP EPS $(0.34) Misses $(0.32) Estimate, As Of June 30, 2024, Larimar Therapeutics Had Cash, Cash Equivalents And Marketable Securities Totaling $226.1M, Which Provides Projected Cash Runway Into 2026

Author: Benzinga Newsdesk | August 07, 2024 07:16am

Posted In: LRMR